Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Crestor Generics of Sawai, Pfizer to Get Listed with Full Indications
Sawai Pharmaceutical and Pfizer Japan said on October 25 that their generic versions of the cholesterol fighter Crestor (rosuvastatin) have won approval for familial hypercholesterolemia (FH), putting them on a level playing field with the originator before their anticipated listing…
To read the full story
Related Article
- More Crestor Generics Now on Equal Footing with Originator
July 20, 2023
- Crestor Generics of Nichi-Iko, Towa Now Have Full Indications
December 27, 2018
BUSINESS
- Toho Builds Alternative Drug Delivery Options for Disaster Readiness
August 25, 2026
- OB/GYN Sees Abrysvo Becoming Part of Prenatal Care as NIP Drives Uptake
August 25, 2026
- Daiichi Sankyo Taps Ken Keller as New Commercial Chief in Global Revamp
August 25, 2026
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…